328 related articles for article (PubMed ID: 26296055)
1. Formulation Design of Dry Powders for Inhalation.
Weers JG; Miller DP
J Pharm Sci; 2015 Oct; 104(10):3259-88. PubMed ID: 26296055
[TBL] [Abstract][Full Text] [Related]
2. Spray-Dried PulmoSphere™ Formulations for Inhalation Comprising Crystalline Drug Particles.
Weers JG; Miller DP; Tarara TE
AAPS PharmSciTech; 2019 Feb; 20(3):103. PubMed ID: 30734187
[TBL] [Abstract][Full Text] [Related]
3. Multi-breath dry powder inhaler for delivery of cohesive powders in the treatment of bronchiectasis.
Young PM; Salama RO; Zhu B; Phillips G; Crapper J; Chan HK; Traini D
Drug Dev Ind Pharm; 2015 May; 41(5):859-65. PubMed ID: 24811055
[TBL] [Abstract][Full Text] [Related]
4. The role of particle properties in pharmaceutical powder inhalation formulations.
Chew NY; Chan HK
J Aerosol Med; 2002; 15(3):325-30. PubMed ID: 12396421
[TBL] [Abstract][Full Text] [Related]
5. Physical Characterization of Tobramycin Inhalation Powder: I. Rational Design of a Stable Engineered-Particle Formulation for Delivery to the Lungs.
Miller DP; Tan T; Tarara TE; Nakamura J; Malcolmson RJ; Weers JG
Mol Pharm; 2015 Aug; 12(8):2582-93. PubMed ID: 26052676
[TBL] [Abstract][Full Text] [Related]
6. Powder, capsule and device: An imperative ménage à trois for respirable dry powders.
Schoubben A; Blasi P; Giontella A; Giovagnoli S; Ricci M
Int J Pharm; 2015 Oct; 494(1):40-8. PubMed ID: 26255220
[TBL] [Abstract][Full Text] [Related]
7. Heat-Stable Dry Powder Oxytocin Formulations for Delivery by Oral Inhalation.
Fabio K; Curley K; Guarneri J; Adamo B; Laurenzi B; Grant M; Offord R; Kraft K; Leone-Bay A
AAPS PharmSciTech; 2015 Dec; 16(6):1299-306. PubMed ID: 25776985
[TBL] [Abstract][Full Text] [Related]
8. Dry powders for oral inhalation free of lactose carrier particles.
Healy AM; Amaro MI; Paluch KJ; Tajber L
Adv Drug Deliv Rev; 2014 Aug; 75():32-52. PubMed ID: 24735676
[TBL] [Abstract][Full Text] [Related]
9. Dose emission characteristics of placebo PulmoSphere® particles are unaffected by a subject's inhalation maneuver.
Weers J; Ung K; Le J; Rao N; Ament B; Axford G; Maltz D; Chan L
J Aerosol Med Pulm Drug Deliv; 2013 Feb; 26(1):56-68. PubMed ID: 22691109
[TBL] [Abstract][Full Text] [Related]
10. Powder Production and Particle Engineering for Dry Powder Inhaler Formulations.
Lin YW; Wong J; Qu L; Chan HK; Zhou QT
Curr Pharm Des; 2015; 21(27):3902-16. PubMed ID: 26290193
[TBL] [Abstract][Full Text] [Related]
11. Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried microparticulate/nanoparticulate antibiotic dry powders of tobramycin and azithromycin for pulmonary inhalation aerosol delivery.
Li X; Vogt FG; Hayes D; Mansour HM
Eur J Pharm Sci; 2014 Feb; 52():191-205. PubMed ID: 24215736
[TBL] [Abstract][Full Text] [Related]
12. A quantitative approach to predicting lung deposition profiles of pharmaceutical powder aerosols.
Yaqoubi S; Chan HK; Nokhodchi A; Dastmalchi S; Alizadeh AA; Barzegar-Jalali M; Adibkia K; Hamishehkar H
Int J Pharm; 2021 Jun; 602():120568. PubMed ID: 33812969
[TBL] [Abstract][Full Text] [Related]
13. Amorphous powders for inhalation drug delivery.
Chen L; Okuda T; Lu XY; Chan HK
Adv Drug Deliv Rev; 2016 May; 100():102-15. PubMed ID: 26780404
[TBL] [Abstract][Full Text] [Related]
14. Formulation of High-Performance Dry Powder Aerosols for Pulmonary Protein Delivery.
Wilson EM; Luft JC; DeSimone JM
Pharm Res; 2018 Aug; 35(10):195. PubMed ID: 30141117
[TBL] [Abstract][Full Text] [Related]
15. Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance.
Bosquillon C; Lombry C; Préat V; Vanbever R
J Control Release; 2001 Feb; 70(3):329-39. PubMed ID: 11182203
[TBL] [Abstract][Full Text] [Related]
16. Low powder mass filling of dry powder inhalation formulations.
Eskandar F; Lejeune M; Edge S
Drug Dev Ind Pharm; 2011 Jan; 37(1):24-32. PubMed ID: 20738180
[TBL] [Abstract][Full Text] [Related]
17. A Novel Technique to Assess Drug Substance Particle Size in a Complex Inhaled Formulation.
Dobson DP; Saggu M; Pellett JD; Tso J
J Pharm Sci; 2023 Sep; 112(9):2385-2388. PubMed ID: 37422282
[TBL] [Abstract][Full Text] [Related]
18. Pulmonary drug delivery by powder aerosols.
Yang MY; Chan JG; Chan HK
J Control Release; 2014 Nov; 193():228-40. PubMed ID: 24818765
[TBL] [Abstract][Full Text] [Related]
19. Dry powder inhalation: past, present and future.
de Boer AH; Hagedoorn P; Hoppentocht M; Buttini F; Grasmeijer F; Frijlink HW
Expert Opin Drug Deliv; 2017 Apr; 14(4):499-512. PubMed ID: 27534768
[TBL] [Abstract][Full Text] [Related]
20. Advanced spray-dried design, physicochemical characterization, and aerosol dispersion performance of vancomycin and clarithromycin multifunctional controlled release particles for targeted respiratory delivery as dry powder inhalation aerosols.
Park CW; Li X; Vogt FG; Hayes D; Zwischenberger JB; Park ES; Mansour HM
Int J Pharm; 2013 Oct; 455(1-2):374-92. PubMed ID: 23820131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]